Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment i...
23 Jun 20215min
Can HMA maintenance therapy improve eligibility for HSCT?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT? Ravand...
17 Mar 20215min
ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and Natasha S. Anstee, The Alfred Hospital & Mo...
2 Feb 202116min
Venetoclax combinations in mutant AML subtypes: IDH1/2
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US, about venetoclax combina...
25 Jan 20216min
Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combin...
20 Jan 20218min
How close are we to offering treatment tailored to mutational profile?
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this ...
8 Jul 20205min
Approaches and emerging therapies for TP53 AML
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to a member of our steering committee, Naval Daver, The University of Texas MD Anderson Cancer Center, Houston,...
1 Jul 202014min
